Claims for Patent: 8,962,034

Summary for Patent: 8,962,034

Title:	Antiviral therapy with a whole, leech saliva extract
Abstract:	Methods are provided for isolating and using a whole-saliva leech extract. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than about 0.degree. C.; and, collecting an unrefined, whole saliva in the regurgitation of the cooled leech. The methods can include revitalizing the leech by warming it at a temperature ranging from about 5.degree. C. to about 40.degree. C. Stable, lyophilized, whole-saliva extracts of a leech are also provided, the extract having a stable activity when stored for use at a temperature below about -20.degree. C., the extract maintaining at least 70% of the activity for at least 6 months. The extracts can be used to treat solid tumors, treat liquid tumors, treat diabetes, treat a viral disease, treat a parasitic disease, treat an antibacterial disease, or serve as an anti-oxidant.
Inventor(s):	Ghawi; Abbas Mohammad (Selangor, MY), Merzouk; Ahmed (Richmond, CA), Abdualkader; Abdualrahman (Pahang, MY), Alaama; Mohamed (Pahang, MY)
Assignee:	Biopep Solutions, Inc. (Richmond, BC, CA)
Application Number:	14/282,893
Patent Claims:	1. A method of treating a viral disease, comprising contacting a virus in a fluid with a whole, leech saliva extract; the extract having a peptide molecular weight distribution with molecular weights of 3496 Daltons or greater, wherein the extract is produced from a process comprising: feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than 0.degree. C. or about 0.degree. C.; and, collecting an unrefined, whole saliva in the regurgitation of the cooled leech. 2. The method of claim 1, further comprising revitalizing the leech by warming the leech in a water bath having a temperature ranging from about 5.degree. C. to about 40.degree. C. 3. The method of claim 1, wherein the method further comprises creating a refined, whole-saliva extract; the creating including removing solid components from the unrefined, whole saliva. 4. The method of claim 1, wherein the method further comprises lyophilizing separate volumes of the refined, whole saliva extract, the volumes not exceeding about 2 ml each. 5. The method of claim 1, the leech being Hirudinaria manillensis. 6. A method of treating a viral disease, comprising: contacting a virus in a fluid with a whole, leech saliva extract; the extract having a peptide molecular weight distribution with a molecular weights of 3496 Daltons or greater; wherein the extract is a lyophilized, whole saliva extract of a leech produced from a method comprising feeding a phagostimulatory agent to a leech; inducing regurgitation in the leech, the inducing including placing the leech in an environment having a temperature ranging from about -5.degree. C. to about 15.degree. C. collecting an unrefined, whole saliva in the regurgitation of the cooled leech; removing solid components from the unrefined, whole saliva to create a refined, whole saliva; and, lyophilizing separate volumes of the refined, whole saliva extract, the volumes not exceeding about 2 ml each. 7. The method of claim 6, further comprising revitalizing the leech by warming the leech in a water bath having a temperature ranging from about 5.degree. C. to about 40.degree. C. 8. The method of claim 7, the leech being Hirudinaria manillensis. 9. The method of claim 1, wherein the fluid is in a subject in need of an antiviral therapy, and the antiviral therapy is used to treat a virus selected from the group consisting of Adenoviridae, Herpesviridae, Papillomaviridae, Polyomaviridae, Poxviridae, Hepadnaviridae, Parvoviridae, Astroviridae, Caliciviridae, Picornaviridae, Coronaviridae, Flaviviridae, Togaviridae, Retroviridae, Orthomyxoviridae, Arenaviridae, Bunyaviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, and Reoviridae. 10. The method of claim 1, wherein the fluid is in a subject in need of an antiviral therapy, and the antiviral therapy is used to treat hepatitis C virus. 11. The method of claim 1, wherein the fluid is in a subject in need of an antiviral therapy, and the antiviral therapy is used to treat HIV. 12. The method of claim 1, wherein the fluid is in a subject in need of an antiviral therapy, and the antiviral therapy is used to treat influenza virus. 13. The method of claim 1, wherein the fluid is in a subject in need of an antiviral therapy, and the antiviral therapy is used to treat West Nile virus. 14. The method of claim 1, wherein the fluid is in a subject in need of an antiviral therapy, and the antiviral therapy is used to treat a virus selected from the group consisting of adenovirus, influenza H1 N1, influenza H5N1, herpes simplex type 1, herpes simplex type 2, varicella-zoster virus, Epstein-Barr virus, human cytomegalovirus, human herpes virus type 8, human papillomavirus, BK virus, JC virus, smallpox, hepatitis B virus, human bocavirus, parvovirus B19, human astrovirus, Norwalk virus, coxsackievirus, hepatitis A virus, poliovirus, rhinovirus, severe acute respiratory syndrome virus, yellow fever virus, dengue virus, rubella virus, and hepatitis E virus. 15. The method of claim 1, wherein the extract is administered in combination with a second agent selected from the group consisting of abacavir, aciclovir, acyclovir, adefovir, amantadine, amprenavir, ampligen, arbidol, atazanavir, atripla, boceprevir, cidofovir, combivir, darunavir, delavirdine, didanosine, docosanol, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, entry inhibitors, famciclovir, fomivirsen, fosamprenavir, foscarnet, fosfonet, fusion inhibitor, ganciclovir, ibacitabine, imunovir, idoxuridine, imiquimod, indinavir, inosine, integrase inhibitor, interferon type III, interferon type II, interferon type I, interferon, lamivudine, lopinavir, loviride, maraviroc, moroxydine, methisazone, nelfinavir, nevirapine, nexavir, oseltamivir, peginterferon alfa-2a, penciclovir, peramivir, pleconaril, podophyllotoxin, protease inhibitor, raltegravir, ribavirin, rimantadine, ritonavir, pyramidine, saquinavir, stavudine, tea tree oil, telaprevir, tenofovir, tenofovir disoproxil, tipranavir, trifluridine, trizivir, tromantadine, truvada, valaciclovir, valganciclovir, vicriviroc, vidarabine, viramidine, zalcitabine, zanamivir, and zidovudine. 16. The method of claim 7, wherein the collecting of the whole saliva yields a peptide molecular weight distribution that ranges from 4276 Daltons to 44386 Daltons. 17. The method of claim 7, wherein the collecting of the whole saliva yields a peptide molecular weight distribution that ranges from 6289 Daltons to 14244 Daltons. 18. The method of claim 7, wherein the collecting of the whole saliva yields a peptide molecular weight distribution that ranges from 10812 Daltons to 88210 Daltons. 19. The method of claim 7, wherein the collecting of the whole saliva yields a peptide molecular weight distribution that ranges from 3496 Daltons to 88210 Daltons.

Details for Patent 8,962,034

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Zr Pharma& Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	10/16/2002		2032-09-17
Zr Pharma& Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	01/07/2004		2032-09-17
Zr Pharma& Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	09/29/2011		2032-09-17